Optimizing clozapine-loaded nanostructured lipid carriers through central composite design for enhance bioavailability in antipsychotic therapy

References

• Iosifescu, D.V. (2012). The relation between mood, cognition and psychosocial functioning in psychiatric disorders. European Neuropsychopharmacology. 22: S499-S504. doi: 10.1016/j.euroneuro.2012.08.002
   PubMed Web of Science ®Google Scholar
• Manjunath, K., Venkateswarlu, V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. Journal of Controlled Release. 107(2): 215-228. doi: 10.1016/j.jconrel.2005.06.006
   PubMed Web of Science ®Google Scholar
• Citrome, L., McEvoy, J.P., Saklad, S.R. (2016). Guide to the management of clozapine-related tolerability and safety concerns. Clinical Schizophrenia & related psychoses. 10(3): 163-177. doi: 10.3371/1935-1232.10.3.163
   PubMedGoogle Scholar
• Kasinathan, J., Mastroianni, T. (2007). Evaluating the use of enforced Clozapine in an Australian forensic psychiatric setting: two cases, BMC Psychiatry. 7(Suppl 1): Page 13.
   Google Scholar
• Abrams, D.J., Zheng, L., Choo, K.S., Yang, J.J., Wei, W., Anchordoquy, T.J., Zawia, N.H., Stevens, K.E. (2008). An initial animal proof-of-concept study for central administration of Clozapine to schizophrenia patients, Schizophrenia research. 100(1-3): 86-96. doi: 10.1016/j.schres.2007.10.012
   PubMed Web of Science ®Google Scholar
• Tareen, F.K., Shah, KU., Ahmad, N., Rehman, A.U., Shah, S.U., Ullah, N. (2020). Proniosomes as a carrier system for transdermal delivery of Clozapine, Drug development industrial pharmacy. 46(6): 946-954. doi: 10.1080/03639045.2020.1764020
   Web of Science ®Google Scholar
• Elmowafy, M., Al-Sanea, M.M. (2021). Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharmaceutical Journal. 29(9): 999-1012. doi: 10.1016/j.jsps.2021.07.015
   PubMed Web of Science ®Google Scholar
• Jawahar, N., Hingarh, P.K., Arun, R., Selvaraj, J., Anbarasan, A., Sathia narayanan, S., Nagaraju, G. (2018). Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. International journal of biological macromolecules. 110: 269-275. doi: 10.1016/j.ijbiomac.2018.01.121
   PubMed Web of Science ®Google Scholar
• Viegas, C., Patrício, A.B., Prata, J.M., Nadhman, A., Chintamaneni, P.K., Fonte, P. (2023). Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review. Pharmaceutics. 15(6): 1593. doi: 10.3390/pharmaceutics15061593
   PubMed Web of Science ®Google Scholar
• Saghafi, Z., Mohammadi, M., Mahboobian, M.M., Derakhshandeh, K. (2021). Preparation, characterization and in vivo evaluation of perphenazine-loaded nanostructured lipid carriers for oral bioavailability improvement. Drug Development and Industrial Pharmacy. 47(3): 509-520. doi: 10.1080/03639045.2021.1892745
   PubMed Web of Science ®Google Scholar
• Fang, C.L., A Al-Suwayeh, S., Fang, J.Y. (2013). Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent patents on nanotechnology. 7(1): 41-55. doi: 10.2174/187221013804484827
   PubMed Web of Science ®Google Scholar
• Kendre, P.N., Pote, A., Bhalke, R., Prajapati, B.G., Jain, S.P., Kapoor, D., (2024). Lipid nanoparticles in targeting Alzheimer's disease. In Alzheimer's Disease and Advanced Drug Delivery Strategies. (283-295). Academic Press.
   Google Scholar
• Deshkar, S., Quazi, A.N., Patil, A., Poddar, S.S. (2015). Effect of Gelucire 44/14 on fluconazole solid lipid nanoparticles: formulation, optimization and in vitro characterization. Drug Delivery Letters. 5(3): 173-187. doi: 10.2174/221030310503160401121141
   Google Scholar
• Sharma, A., Sood, A., Mehta, V., Malairaman, U. (2016). Formulation and physicochemical evaluation of nanostructured lipid carrier for codelivery of clotrimazole and ciprofloxacin. Asian J. Pharm. Clin. Res. 9(3): 356-360
   Google Scholar
• Agrawal, M., Saraf, S., Pradhan, M., Patel, R.J., Singhvi, G., Alexander, A. (2021). Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design. Biomedicine & Pharmacotherapy. 141: 111919. doi: 10.1016/j.biopha.2021.111919
   PubMed Web of Science ®Google Scholar
• Cunha, S., Costa, C.P., Loureiro, J.A., Alves, J., Peixoto, A.F., Forbes, B., Sousa Lobo, J.M., Silva, A.C. (2020). Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters. Pharmaceutics. 12(7): 599. doi: 10.3390/pharmaceutics12070599
   PubMed Web of Science ®Google Scholar
• Correia, A.C., Moreira, J.N., Sousa Lobo, J.M., Silva, A.C. (2023). Design of experiment (DoE) as a quality by design (QbD) tool to optimise formulations of lipid nanoparticles for nose-to-brain drug delivery. Expert Opinion on Drug Delivery. 1-18.
   Web of Science ®Google Scholar
• Rabima, R., Sari, M.P. (2019). Entrapment efficiency and drug loading of curcumin nanostructured lipid carrier (NLC) formula. Pharmaciana. 9(2): 299-306. doi: 10.12928/pharmaciana.v9i2.13070
   Google Scholar
• Jazuli, I., Nabi, B., Alam, T., Baboota, S., Ali, J. (2019). Optimization of nano-structured lipid carriers of lurasidone hydrochloride using Box-Behnken design for brain targeting: in vitro and in vivo studies. Journal of Pharmaceutical Sciences. 108(9): 3082-3090. doi: 10.1016/j.xphs.2019.05.001
   PubMed Web of Science ®Google Scholar
• Montoto, S.S., Sbaraglini, M.L., Talevi, A., Couyoupetrou, M., Di Ianni, M., Pesce, G.O., Alvarez, V.A., Bruno-Blanch, L.E., Castro, G.R., Ruiz, M.E., Islan, G.A. (2018). Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: physicochemical characterization and in vitro/ in vivo evaluation. Colloids and Surfaces B: Biointerfaces. 167: 73-81. doi: 10.1016/j.colsurfb.2018.03.052
   PubMed Web of Science ®Google Scholar
• Tirumalesh, C., Suram, D., Dudhipala, N., Banala, N. (2020). Enhanced pharmacokinetic activity of Zotepine via nanostructured lipid carrier system in Wistar rats for oral application. Pharmaceutical nanotechnology. 8(2): pp.148-160. doi: 10.2174/2211738508666200225113359
   PubMedGoogle Scholar
• Patel, D., Kesharwani, R., Gupta, S. (2015). Development & screening approach for lipid nanoparticle: A review. Asian Journal of Pharmaceutical Research and Development. 1-7.
   Google Scholar
• Unnisa, A., Chettupalli, A.K., Alazragi, R.S., Alelwani, W., Bannunah, A.M., Barnawi, J., Amarachinta, P.R., Jandrajupalli, S.B., Elamine, B.A., Mohamed, O.A., Hussain, T. (2023). Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations. Pharmaceuticals. 16(8): 1151. doi: 10.3390/ph16081151
   Web of Science ®Google Scholar
• Subramaniam, B., Siddik, Z.H., Nagoor, N.H. (2020). Optimization of nanostructured lipid carriers: Understanding the types, designs and parameters in the process of formulations. Journal of nanoparticle research. 22: 1-29. doi: 10.1007/s11051-019-4718-8
   PubMed Web of Science ®Google Scholar
• Grewal, I.K., Singh, S., Arora, S., Sharma, N. (2021). Application of central composite design for development and optimization of eflornithine hydrochloride-loaded sus-tained release solid lipid microparticles. Biointerface Res. Appl. Chem. 112: 618-637.
   Google Scholar
• Ye, Q., Li, J., Li, T., Ruan, J., Wang, H., Wang, F., Zhang, X. (2021). Development and evaluation of puerarin-loaded controlled release nanostructured lipid carries by central composite design. Drug Development and Industrial Pharmacy. 47(1): 113-125. doi: 10.1080/03639045.2020.1862170
   PubMed Web of Science ®Google Scholar
• Avula, P.R., Chettupalli, A.K., Chauhan, V., Jadi, R.K. (2023). Design, formulation, in-vitro and in-vivo pharmacokinetic evaluation of Nicardipine-nanostructured lipid carrier for transdermal drug delivery system. Materials Today: Proceedings.
   Google Scholar
• Managuli, R.S., Wang, J.T., Faruqu, F.N., Kushwah, V., Raut, S.Y., Shreya, A.B., Al-Jamal, K.T., Jain, S., Mutalik, S. (2019). Asenapine maleate-loaded nanostructured lipid carriers: optimization and in vitro, ex vivo and in vivo evaluations. Nanomedicine. 14(7): 889-910. doi: 10.2217/nnm-2018-0289
   PubMed Web of Science ®Google Scholar
• Singh, S.K., Dadhania, P., Vuddanda, P.R., Jain, A., Velaga, S., Singh, S. (2016). Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioral assessment. RSC advances. 6(3): 2032-2045. doi: 10.1039/C5RA19793G
   Web of Science ®Google Scholar
• Kesharwani, D., Paul, S.D., Paliwal, R., Satapathy, T. (2023). Development, QbD-based optimization and in vitro characterization of Diacerein loaded nanostructured lipid carriers for topical applications. Journal of Radiation Research and Applied Sciences. 16(2): pp.100565. doi: 10.1016/j.jrras.2023.100565
   Web of Science ®Google Scholar
• Neha, S.L., Mishra, A.K., Rani, L., Paroha, S., Dewangan, H.K., Sahoo, P.K. (2023). Design and evaluations of a nanostructured lipid carrier loaded with dopamine hydrochloride for intranasal bypass drug delivery in Parkinson’s disease. Journal of Microencapsulation. 40(8): 599-612. doi: 10.1080/02652048.2023.2264386
   PubMed Web of Science ®Google Scholar
• Ghaderi, S., Ghanbarzadeh, S., Mohammad-hassani, Z., Hamishehkar, H. (2014). Formulation of gammaoryzanol-loaded nanoparticles for potential application in fortifying food products. Advanced pharmaceutical bulletin. 4(Suppl 2): 549.
   PubMedGoogle Scholar
• Radwan, I.T., Ghazawy, N.A.R., Alkhaibari, A.M., Gattan, H.S., Alruhaili, M.H., Selim, A., Salem, M.E., AbdelFattah, E.A., Hamama, H.M. (2024). Nanostructure Lipid Carrier of Curcumin Co-Delivered with Linalool and Geraniol Monoterpenes as Acetylcholinesterase Inhibitor of Culex pipiens. Molecules. 29(1): 271. doi: 10.3390/molecules29010271
   PubMed Web of Science ®Google Scholar
• Dudhipala, N., Janga, K.Y., Gorre, T. (2018). Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artificial cells, nanomedicine and biotechnology. 46(sup2): 616-625. doi: 10.1080/21691401.2018.1465068
   PubMed Web of Science ®Google Scholar
• Gu, L., Wang, W., Wu, B., Ji, S., Xia, Q. (2023). Preparation and in vitro characterization studies of astaxanthin-loaded nanostructured lipid carriers with antioxidant properties. Journal of Biomaterials Applications. 38(2): 292-301. doi: 10.1177/08853282231189779
   PubMed Web of Science ®Google Scholar
• Sivadasu, P., Gowda, D.V., Subramani, N.K., Malgur, B., Vishweshwaraiah, S.S., Hatna, S. (2020). Direct brain targeted nanostructured lipid carriers for sustained release of schizophrenic drug: Formulation, characterization and pharmacokinetic studies. brain. 9: 12.
   Google Scholar
• Devi, J., Gautam, M.K., Syamala, G.J., Khan, A., Kumar, S., Sharma, D., Goda, C. (2023). Nanostructured Lipid Carrier Development and Optimization for Schizophrenia: A Psychological Study. Journal for Reattach Therapy and Developmental Diversities. 6(9s2): 10-526.
   Google Scholar